Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 842-849

  Bissett, Donald ^a   O'Byrne, Ken J ^a   Von Pawel, J ^a   Gatzemeier, Ulrich ^a   Price, Allan ^a   Nicolson, Marianne ^a   Mercier, Richard ^a   Mazabel, Elva ^a   Penning, Carol ^a   Zhang, Min H ^a   Collier, Mary A ^a   Shepherd, Frances A ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PLACEBO; PRINOMASTAT; MATRIX METALLOPROTEINASE; ORGANIC COMPOUND; PROTEINASE INHIBITOR;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JOINT SWELLING; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; DRUG ANTAGONISM; LUNG TUMOR; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; ORGANIC CHEMICALS; PROTEASE INHIBITORS;

EID: 20044388325     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.170     Document Type: Article

References (23)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
3. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
4. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
5. Nelson AR, Fingleton B, Rothenberg ML, et al: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18:1135-1149, 2000
6. Scatena R: Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor: A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs 9:2159-2165, 2000
7. Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002
8. Price A, Shi Q, Morris D, et al: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5:845-854, 1999
9. Shalinsky DR, Brekken J, Zou H, et al: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 878:236-270, 1999
10. Shalinsky DR, Brekken J, Zou H, et al: Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies. Clin Cancer Res 5:1905-1917, 1999
11. Bonomi P: Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 29:78-86, 2002
12. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270, 1997
13. Smylie M, Mercier R, Aboulafia D, et al: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20:307a, 2001 (abstr 1226)
14. Pritchard SC, Nicolson MC, Lloret C, et al: Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: Implications for MMP inhibition therapy. Oncol Rep 8:421-424, 2001
15. Thomas P, Khokha R, Shepherd FA, et al: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190:150-156, 2000
16. Michael M, Babic B, Khokha R, et al: Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17:1802-1808, 1999
17. Cox G, Jones JL, O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6:2349-2355, 2000
18. Ahmann F, Saad F, Mercier R, et al: Interim results of a phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 20:174a, 2001 (abstr 692)
19. Behrendt CE, Ruiz RB: Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 90:734-737, 2003
20. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167, 2002
21. Bramhall SR, Hallissey MT, Whiting J, et al: Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 86:1864-1870, 2002
22. Miller KD, Gradishar W, Schuchter L, et al: A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 13:1220-1224, 2002
23. Levitt NC, Eskens FA, O'Byrne KJ, et al: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7:1912-1922, 2001